22.83
6.82 (42.60%)
| Previous Close | 16.01 |
| Open | 21.99 |
| Volume | 21,265,063 |
| Avg. Volume (3M) | 1,137,148 |
| Market Cap | 1,486,638,464 |
| Price / Earnings (TTM) | 71.34 |
| Price / Sales | 7.15 |
| Price / Book | 4.15 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 3.86% |
| Operating Margin (TTM) | 51.85% |
| Diluted EPS (TTM) | 0.120 |
| Quarterly Revenue Growth (YOY) | 7,882.00% |
| Total Debt/Equity (MRQ) | 15.21% |
| Current Ratio (MRQ) | 5.61 |
| Operating Cash Flow (TTM) | 34.67 M |
| Levered Free Cash Flow (TTM) | 40.54 M |
| Return on Assets (TTM) | -0.40% |
| Return on Equity (TTM) | 2.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Monte Rosa Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | 0.0 |
| Price Volatility | -4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.70 |
|
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.73% |
| % Held by Institutions | 101.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aisling Capital Management Lp | 30 Sep 2025 | 1,472,331 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 34.00 (Guggenheim, 48.93%) | Buy |
| Median | 32.00 (40.17%) | |
| Low | 30.00 (Wells Fargo, 31.41%) | Buy |
| Average | 32.00 (40.17%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 22.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 08 Jan 2026 | 34.00 (48.93%) | Buy | 22.96 |
| Wells Fargo | 08 Jan 2026 | 30.00 (31.41%) | Buy | 22.96 |
| 16 Dec 2025 | 22.00 (-3.64%) | Buy | 18.66 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHAMPOUX JENNIFER | 15.31 | 14.40 | 32,371 | 497,992 |
| DUNN EDMUND | - | 14.40 | -1,039 | -14,962 |
| JANKU FILIP | 15.31 | 14.40 | 27,845 | 429,178 |
| NICKSON PHILIP | 15.31 | 14.40 | 24,845 | 383,248 |
| TOWNSON SHARON | 15.31 | 14.40 | 31,845 | 490,418 |
| WARMUTH MARKUS | 15.31 | 14.40 | 79,865 | 1,231,956 |
| Aggregate Net Quantity | 195,732 | |||
| Aggregate Net Value ($) | 3,017,831 | |||
| Aggregate Avg. Buy ($) | 15.31 | |||
| Aggregate Avg. Sell ($) | 14.40 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TOWNSON SHARON | Officer | 05 Jan 2026 | Sell (-) | 3,155 | 14.40 | 45,432 |
| JANKU FILIP | Officer | 05 Jan 2026 | Sell (-) | 3,155 | 14.40 | 45,432 |
| WARMUTH MARKUS | Officer | 05 Jan 2026 | Sell (-) | 10,135 | 14.40 | 145,944 |
| DUNN EDMUND | Officer | 05 Jan 2026 | Sell (-) | 1,039 | 14.40 | 14,962 |
| CHAMPOUX JENNIFER | Officer | 05 Jan 2026 | Sell (-) | 2,629 | 14.40 | 37,858 |
| NICKSON PHILIP | Officer | 05 Jan 2026 | Sell (-) | 3,155 | 14.40 | 45,432 |
| TOWNSON SHARON | Officer | 02 Jan 2026 | Acquired (+) | 35,000 | 15.31 | 535,850 |
| JANKU FILIP | Officer | 02 Jan 2026 | Acquired (+) | 31,000 | 15.31 | 474,610 |
| WARMUTH MARKUS | Officer | 02 Jan 2026 | Acquired (+) | 90,000 | 15.31 | 1,377,900 |
| CHAMPOUX JENNIFER | Officer | 02 Jan 2026 | Acquired (+) | 35,000 | 15.31 | 535,850 |
| NICKSON PHILIP | Officer | 02 Jan 2026 | Acquired (+) | 28,000 | 15.31 | 428,680 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |